Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | SPR | P35270 | 1/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6775636 | 0.92 | MAPT (0.48) | SIGMAR1SMN1; SMN2NOTUMMAPTTDP1 | |
| SCHEMBL6774952 | 0.92 | MAPT (0.55) | SIGMAR1SMN1; SMN2NOTUMMAPTTDP1 | |
| SCHEMBL6770333 | 0.87 | GPBAR1 (0.49) | SIGMAR1SMN1; SMN2MAPTTDP1SPR | |
| SCHEMBL7098241 | 0.84 | ATM (0.51) | SIGMAR1SMN1; SMN2NOTUMMAPTTDP1 | |
| SCHEMBL6776139 | 0.84 | MAPT (0.56) | SIGMAR1SMN1; SMN2NOTUMMAPTTDP1 | |
| SCHEMBL6769257 | 0.83 | SIGMAR1 (0.50) | SIGMAR1SMN1; SMN2NOTUMMAPTTDP1 | |
| SCHEMBL7104470 | 0.82 | SIGMAR1 (0.45) | SIGMAR1SMN1; SMN2NOTUMMAPTTDP1 | |
| SCHEMBL6768618 | 0.82 | SIGMAR1 (0.58) | SIGMAR1SMN1; SMN2NOTUMMAPTTDP1 | |
| SCHEMBL7026550 | 0.81 | MAPT (0.43) | SIGMAR1SMN1; SMN2NOTUMMAPTTDP1 | |
| SCHEMBL6768665 | 0.81 | MAPT (0.50) | SIGMAR1SMN1; SMN2NOTUMMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153763-A1 | Pharmaceutically active compounds and methods of use | WYETH | 2003-08-14 | — | — | US | claimed |
| US-20020099084-A1 | Pharmaceutically active compounds and methods of use | WYETH | 2002-07-25 | — | — | US | claimed |
| EP-0925300-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-06-30 | — | — | EP | claimed |
| EP-0925300-A4 | — | — | 1999-06-30 | — | — | EP | claimed |
| WO-1997030054-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1999002145-A1 | COMBINATION DRUG THERAPIES COMPRISING AMINOGLYCOSIDE ANTIBIOTICS AND N,N'-DISUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153763-A1 | Pharmaceutically active compounds and methods of use | ACHE, PARK7, NLN | SIGMAR1 2813/4885SMN1; SMN2 104/4885NOTUM 439/4885 |
| US-20020099084-A1 | Pharmaceutically active compounds and methods of use | ACHE, PARK7, NLN | SIGMAR1 2813/4885SMN1; SMN2 104/4885NOTUM 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.